Empowering Innovation for
Military Medicine and Beyond
Diagnose
Treat
Recovery
Turning breakthrough ideas into scalable medical innovations that revolutionize defense healthcare and improve lives worldwide.
SelasBio works with groundbreaking medical entrepreneurs and technologies overlooked by traditional venture capital by focusing on defense healthcare challenges, providing early funding, and leveraging military use cases to drive scalable societal impact.
Navigating
DoD Pathways
We leverage our team’s expertise and military connections to identify DoD needs, secure first funding, and access first customers through SBIR/STTR and other DoD initiatives.
Transforming Technology Success
Driving the translation of cutting-edge research into market-ready solutions through exceptional productization and commercialization expertise.
Our Portfolio
Leadership / Science
Government
Contact Us
San Francisco | Boston | San Antonio | New York
© SelasBio. All rights reserved.
Trevor Perry is the CEO of SelasBio and a founding partner of Selas Ventures, where he leads a portfolio of defense healthcare and military medicine ventures built to move life-saving diagnostics and therapeutics through DoD and federal pathways faster than industry norms allow.Trevor is an experienced CEO and founder with a track record of building and scaling biotech companies from the ground up. His foundation is in military leadership and medicine: as a U.S. Army NCO, he led and trained medical teams in triage and battlefield care, an experience that shaped his approach to building organizations that perform under pressure and execute with discipline.He spent over a decade in pharmaceutical commercialization, helping launch Lexapro, Namenda, and Bystolic at Forest Laboratories and leading business development at ReproCELL and Stemgent. In 2016, he founded GoodCell, the first personal biobank in the U.S., raising more than $45M and commercializing diagnostics for clonal hematopoiesis (CHIP).
Brad Hamilton is the co-founder and Chief Scientific Officer of SelasBio, where he leads the development and commercialization of technologies across the company portfolio.With more than 25 years of biotechnology leadership experience in drug discovery and cell and gene therapy, Brad has founded and led multiple venture-backed biotechnology companies - developing breakthrough platform technologies in multiplexed orthogonal gene switches, epigenetic modification, RNA interference (RNAi), embryonic and induced pluripotent stem cell (ES/iPSC) derivation and engineering, and blood bioprocessing.Throughout his career, he has led the development of more than 100 life science products with research and clinical applications, contributing to multiple successful company exits with a combined value exceeding $300 million dollars.Brad holds a B.S. in Biology from James Madison University and an M.S. in Biotechnology from the University of Tennessee.
Bethany Grant is CTO and Head of Targeted Delivery at SelasBio, leading the advancement of novel therapeutic and diagnostic technologies.She is a seasoned MedTech executive, engineer, and technology leader with more than 25 years of experience developing innovative healthcare solutions from concept through commercialization, and is recognized for her ability to identify emerging opportunities, build high-performing teams, and translate breakthrough science into impactful products that improve patient care and commercial outcomes.Bethany has a B.S. and M.S. in Aeronautics and Astronautics from MIT, is an inventor on multiple U.S. patents spanning medical devices, regenerative medicine, digital workflows, and therapeutic delivery technologies, and has contributed to scientific publications in biomedical engineering and healthcare innovation.
Dr. Conway holds a PhD in Clinical Hematology and has held academic appointments at Harvard Medical School and the University of Maryland. She served as Program Director for the DOD FSHARP program, directing a multidisciplinary blood-products research effort of direct relevance to far-forward resuscitation.Her expertise spans transfusion medicine, artificial and engineered blood products, red cell biology, and sickle cell disease, with extensive experience bridging clinical practice, industry, and translational research.
Mike Smith is the Senior Advisor for Special Operations at SelasBio, where he provides operational expertise and strategic guidance to support the development and transition of technologies for defense and national security applications.
Mike brings more than 27 years of U.S. Air Force and special operations experience, with leadership roles spanning Air Force Special Tactics, Joint Special Operations Command, and the USAF Weapons School. His career includes service as a Special Tactics Squadron Commander, JSOC Task Force Director, Director of Operations, and Chief of Weapons and Tactics. He also founded and commanded the Air Force’s first Joint Terminal Attack Controller Weapons Instructor Course.Throughout his career, Mike has led high-performing organizations in complex operational environments and helped develop capabilities, tactics, and training for some of the nation’s most specialized military forces. Following his military service, he has continued working at the intersection of defense, emerging technology, and commercialization, helping technology companies translate innovative products into operational capabilities for the Department of Defense.Mike is a graduate of the USAF Weapons School and holds a Master of Science degree in Operational Warfare from the Air War College.
Dr. Joseph Burdo, MBA, Ph.D., is a neuroscientist, biotechnology executive, and scientific strategist with more than two decades of experience spanning academic research, translational medicine, and biotechnology commercialization. He earned his Ph.D. in Neuroscience from Penn State College of Medicine and combines a strong scientific foundation with an MBA to bridge cutting-edge biomedical innovation with strategic business development.Throughout his career, Dr. Burdo has led multidisciplinary research programs focused on neuroscience, neurodegeneration, biomarkers, inflammation, and precision medicine while helping organizations translate promising discoveries into commercially viable technologies. He has extensive experience developing competitive federal funding proposals, advancing early-stage technologies, and guiding product development from concept through commercialization.In addition to his scientific leadership, Dr. Burdo has become recognized for his expertise in research strategy, grant development, and emerging biotechnology opportunities. He has worked closely with startups, academic investigators, and industry partners to secure non-dilutive funding, develop intellectual property strategies, and accelerate innovation in diagnostics, therapeutics, and medical technologies. His work integrates neuroscience, biomarker discovery, artificial intelligence, and translational research to address significant unmet medical needs in neurological disease, cardiovascular disease, and military medicine.Dr. Burdo is committed to advancing technologies that improve patient outcomes while strengthening the nation's biomedical innovation ecosystem through collaboration among academia, industry, government, and investors.
Brian Hermes is Chief of Staff at Selas Ventures and SelasBio, where he works across portfolio companies to identify high-value use cases, shape go-to-market strategies, build stakeholder alignment, and unlock non-dilutive and strategic funding.
A retired U.S. Air Force veteran and innovation operator, Brian has built his career at the intersection of national defense, venture strategy, and startup execution. He has led Air Force innovation initiatives spanning software engineering, mobile applications, and biotechnology, while supporting emerging technologies through SBIR, STTR, and CRADA pathways.Throughout his career, Brian has worked with founders, investors, and government partners to translate complex military and commercial needs into actionable strategies. His experience includes business development, defense venture fellowship, and strategic partnership building, focusing on technologies that strengthen readiness, improve human performance, expand access to critical capabilities, and create lasting value for the warfighter and the broader market.Brian holds an MBA and B.A. in Business Administration and Management from the University of the Incarnate Word. He is also a Certified Innovation Coach, a Lean Six Sigma Black Belt, and a graduate of VC University from U.C. Berkeley Law School.
James Cazort is a senior defense health strategist and retired U.S. Air Force Medical Service Corps officer with 20 years of leadership across military healthcare, readiness, operations, and enterprise strategy.His Air Force career included executive and operational roles spanning healthcare and research finance, medical logistics, clinical operations, workforce strategy, and austere surgical operations. As Senior Advisor, Military Medicine at SelasBio, James advises leadership and portfolio companies on positioning high-potential medical technologies for adoption across the Department of Defense and federal health markets—aligning innovation with mission-critical needs and advancing credible pathways to funding, validation, procurement, and scale.
Stellar Notch is building a targeted therapeutic delivery platform designed to direct regenerative and biologic payloads to specific cells and tissues. The company’s nanoparticle-based technology protects, transports, and concentrates therapeutic cargo at sites of injury or disease, helping overcome delivery limitations that constrain advanced medicines. Stellar Notch is building beyond a single treatment, creating a platform that can support multiple therapeutic applications across trauma, brain injury, wound healing, and regenerative medicine. This approach is designed for high-need clinical and military environments where precision delivery, deployability, and improved treatment timing can expand the impact of next-generation therapeutics.
WayFinder Genetics is building a field-deployable detection platform designed to generate actionable biological insight when centralized laboratory testing is unavailable or too slow. The company’s biosensing technology balances detection across sample types, including blood, saliva, urine, and swabs, to support both pathogen identification and blood metabolite testing at the point of need. Rather than developing a single assay, WayFinder is creating a flexible platform for infectious disease, physiologic monitoring, triage, and operational health applications across military medicine, remote care, urgent care, hospitals, and biodefense.
MindMark Health is building a brain health platform designed to convert objective neurological data into actionable insight for earlier diagnosis, monitoring, and intervention. The company’s technology combines noninvasive assessment, advanced analytics, and longitudinal tracking to identify meaningful changes in cognitive and neurological function over time. Rather than creating a single assessment tool, MindMark Health is developing a scalable platform that can support novel diagnostics, patient stratification, treatment-response monitoring, and the development of targeted therapeutic interventions. Its applications span military medicine, remote care, clinical research, and healthcare systems seeking objective, repeatable tools for brain health decision-making.
NuOrigen is building an intelligence layer for precision drug delivery that matches therapeutic cargo to the optimal carrier, loading method, and stabilization strategy. The company combines an AI-enabled intelligence layer with research and manufacturing capabilities to turn carrier-cargo selection from intuition into a repeatable system. NuOrigen is creating a modality-agnostic platform for informed therapeutic delivery approaches, spanning extracellular vesicles, red blood cells, lipid nanoparticles, and future delivery vehicles. As solutions are validated through in vitro and in vivo testing, the platform’s data layer is strengthened, improving the quality and lowering the cost of subsequent programs, and enabling new diagnostics, therapeutics, licensing, and spinout opportunities.
WildType Bio is building a shelf-stable blood platform designed to make transfusion-ready components available wherever blood is needed but cold-chain logistics fail. The company’s technology dries, stores, verifies, reconstitutes, and delivers donor-derived blood components through shared manufacturing, validation, and device infrastructure. Rather than creating a single product, WildType Bio is developing a multi-component system that can support red cells, plasma, platelets, and future cellular therapies on common platform rails. Its military-first strategy targets austere care, trauma response, and Defense Health Agency procurement, with broader applications across EMS, disaster response, rural medicine, and global trauma systems.